Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RAPP | 144 | bearish | 5/10 | Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 on May 27, 2026, indicating intent to sell 18,572 share | May 27, 2026 |
| JAGX | 8-K | neutral | 4/10 | Jaguar Health received formal notice from Nasdaq on May 26, 2026 that it has regained compliance with the $1.00 bid pric | May 27, 2026 |
| AZN | COURT-RULING | neutral | 4/10 | The Delaware Court of Chancery ruled that Syntimmune (acquired by AstraZeneca/Alexion) breached its merger agreement rep | May 27, 2026 |
| MYGN | PRESS-RELEASE | neutral | 4/10 | Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection | May 27, 2026 |
| MNKD | PRESS-RELEASE | bullish | 7/10 | MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy, treatment satisfac | May 27, 2026 |
| MTVA | 8-K | bullish | 6/10 | MetaVia Inc. (MTVA) disclosed Phase 1 data for DA-1726 at EASL 2026. The 48 mg cohort showed up to 9.1% mean body weight | May 27, 2026 |
| BAK | 6-K | neutral | 3/10 | Braskem filed a consolidated summary report of remote voting for its Extraordinary General Meeting, originally called fo | May 27, 2026 |
| TRAW | 8-K | neutral | 4/10 | Traws Pharma announced a new broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks, utilizing a prop | May 27, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber filed a provisional patent for a Coaxial Dual-Propellant Grain Solid Rocket Motor (CDPG-SRM) that extends | May 27, 2026 |
| LNZA | PRESS-RELEASE | neutral | 1/10 | LanzaTech Inc. announced it will report its Q2 2026 results on August 14, 2026. | May 27, 2026 |
| HOTH | 8-K | neutral | 4/10 | Hoth Therapeutics completed a name change to Rocket One Inc. (ticker RKTO), effective May 26, 2026, and announced an exc | May 27, 2026 |
| ALT | PRESS-RELEASE | neutral | 2/10 | Altimmune announced management participation in upcoming investor conferences, a routine corporate event with no materia | May 27, 2026 |
| BIAFW | 8-K | neutral | 4/10 | bioAffinity Technologies announced it received a notification of allowance from the Mexican Institute of Industrial Prop | May 27, 2026 |
| ERNA | PRESS-RELEASE | neutral | 4/10 | Ernexa Therapeutics provided a business update press release highlighting progress on its lead candidate ERNA-101, inclu | May 27, 2026 |
| ENLV | 6-K | bullish | 6/10 | Enlivex issued a press release commenting on the Rain Foundation's $100M liquidity commitment to the Rain prediction mar | May 27, 2026 |
| MIRA | 8-K | bullish | 5/10 | MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide rights and added inter | May 27, 2026 |
| HCWB | 8-K | bullish | 6/10 | HCW Biologics terminated its exclusive worldwide license with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206, rega | May 27, 2026 |
| NCEL | PRESS-RELEASE | neutral | 5/10 | NewcelX announced submission of a Pre-IND briefing package to the FDA for NCEL-101 (stem-cell-derived islet therapy) com | May 27, 2026 |
| ZEOX | 8-K | neutral | 2/10 | ZEO ScientifiX announced the formal launch of its Physician-Led Patient Masterclass program, a patient education initiat | May 27, 2026 |
| DTIL | 8-K | bullish | 7/10 | Precision BioSciences announced new and late-breaking clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in | May 27, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of Novembe | May 27, 2026 |
| BLRX | 6-K | mixed | 5/10 | BioLineRx reported Q1 2026 results: royalty revenues of $0.5M (up from $0.3M YoY) but operating loss widened to $3.0M fr | May 27, 2026 |
| MDWD | PRESS-RELEASE | bearish | 5/10 | MediWound reported Q1 2026 revenue of $1.5M, down 62% YoY from $4.0M, and a net loss of $0.23 per share, wider than the | May 27, 2026 |
| APGE | 8-K | bullish | 7/10 | Apogee Therapeutics entered into a revenue participation agreement with Blackstone Life Sciences for up to $1.3 billion | May 27, 2026 |
| APGE | 8-K | bullish | 7/10 | Apogee Therapeutics announced positive 16-week induction dose optimization results from Part B of the Phase 2 APEX trial | May 27, 2026 |
| APGE | PRESS-RELEASE | bullish | 7/10 | Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion i | May 27, 2026 |
| APGE | PRESS-RELEASE | bullish | 8/10 | Apogee Therapeutics announced positive 16-week Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic de | May 27, 2026 |
| AZN | 6-K | mixed | 6/10 | AstraZeneca announced the FDA extended the PDUFA date for camizestrant in HR+/HER2- advanced breast cancer to review add | May 27, 2026 |
| NGEN | EFFECT | neutral | 4/10 | The SEC declared effective NERVGEN PHARMA CORP.'s registration statement (File No. 333-296217) on May 26, 2026, under th | May 27, 2026 |
| NONOF | 6-K | neutral | 3/10 | Novo Nordisk filed a 6-K to report ongoing share repurchase activity under a pre-announced program. Since 4 February 202 | May 27, 2026 |